Subject: | |
From: | |
Reply To: | |
Date: | Fri, 11 Jun 2004 11:11:16 -0400 |
Content-Type: | text/plain |
Parts/Attachments: |
|
|
All Janssen has to do is make an extended release form in the right dose
for improving lactation, and then submit it as a substantial
improvement. Voila, new patent. US manufacturers do it all the time!
Tegretol (carbamazepine- an anticonvulsant)--Tegretol XR (extended
release carbamazepine through an indigestible tablet with a pinhole to
let the drug out in controlled amounts)--Carbatrol (extended release
carbamazepine by controlled dissolution) and finally Trileptal
(oxcarbamazepine - adding that tiny group totally changes metabolism of
the drug, avoiding the most problematic metabolite (carbamazepine
epoxide) in terms of side effects, without reducing the effectiveness of
the drug.)
I certainly think it would be worth their money, or anyone else's.
Catherine Watson Genna, BS, IBCLC NYC
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|